Recent Updates
Recently added Catalysts
ANTX Positive Sentiment

AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting

Monday, August 31, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: AN2 Therapeutics has announced the presentation of four abstracts at the Society of Hematologic Oncology 2026 Annual Meeting. These abstracts will showcase clinical and nonclinical data supporting the development of epetraborole, an innovative oral treatment for polycythemia vera. This highlights the company's ongoing commitment to advancing novel therapeutics.

Market Sentiment Analysis

POSITIVE FACTORS

  • Presentation of four abstracts at a significant conference.
  • Focus on a novel treatment for polycythemia vera.
  • Support from clinical and nonclinical data.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+8%
120-day peak, hindsight
Typical move
30.5%
average across 2 past catalysts
Cash runway
~34 mo
Minimal dilution risk
Lead asset
Epetraborole
Phase 2 · Mycobacterium Abscessus Infection

Full Press Release Details

MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today announced that four abstracts highlighting clinical and nonclinical data supporting the development of epetraborole, a novel boron-containing oral candidate for the treatment of polycythemia vera (PV), will be presented at the Society of Hematologic Onc

Frequently Asked Questions

What is epetraborole?

Epetraborole is a novel boron-containing oral candidate for treating polycythemia vera.

Where was the data on epetraborole presented?

The data was presented at the Society of Hematologic Oncology 2026 Annual Meeting.

How many abstracts were presented by AN2 Therapeutics?

AN2 Therapeutics presented four abstracts highlighting their research.

What type of data supports epetraborole's development?

Both clinical and nonclinical data support the development of epetraborole.

ShareAdd on Google
Tags: ANTX Viatris Investor Conferences Healthcare AN2 Therapeutics epetraborole polycythemia vera SOHO 2026 clinical data
Last updated: Aug 31, 2026

Biotech snapshot

Cash runway
$80M liquidity · $2M/mo burn
~34 mo
Minimal dilution risk
Lead asset
EpetraborolePhase 2
Mycobacterium Abscessus Infection →

Catalyst track record

+8%
best trade around ANTX's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for ANTX.

See every catalyst's timing & PoA →